Julie M Vose, MD, MBA
Dreyling M et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28(Suppl 4);62-71. Abstract
Fernandez V et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 2010;70(4):1408-18. Abstract
Ferrando AA. SOX11 is a mantle cell lymphoma oncogene. Blood 2013;121(12):2169-70. Abstract
Fisher RI et al. Diffuse aggressive lymphoma. Hematology Am Soc Hematol Educ Program 2004;221-36. Abstract
Hoster E et al. Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: Results from randomized trials of the European Mantle Cell Lymphoma Network. J Clin Oncol 2016;34(12):1386-94. Abstract
Hoster E et al. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. J Clin Oncol 2014;32(13):1338-46. Abstract
Hoster E et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008;111(2):558-65. Abstract
Le Gouill S et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med 2017;377(13):1250-60. Abstract
Lichtman MA et al. Williams Hematology. 7th ed. New York, NY: McGraw Hill; 2006.
Martin P et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009;27(8):1209-13. Abstract
Rummel MJ et al. Two years rituximab maintenance vs observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: First results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial). Proc ASCO 2016;Abstract 7503.
Rummel MJ et al.Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013;381(9873):1203-10. Abstract
Seto M. Cyclin D1-negative mantle cell lymphoma. Blood 2013;12(8):1249-50. Abstract
Vegliante MC et al. SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. Blood 2013;121(12):2175-85. Abstract
Wang ML et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013;369(6):507-16. Abstract
John P Leonard, MD
Baiocchi RA et al. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. Cancer 2011;117(11):2442-51. Abstract
Dietrich S et al. Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: A retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol 2014;25(5):1053-8. Abstract
Eskelund CW et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood 2017;130(17):1903-10. Abstract
Fenske TS et al. Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: Analysis of transplantation timing and modality. J Clin Oncol 2014;32(4)273-81. Abstract
Friedberg JW et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 2011;117(10):2807-12. Abstract
Furtado M et al. Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma. Br J Haematol 2015;168(1):55-62. Abstract
García-Noblejas A et al. Bendamustine as salvage treatment for patients with relapsed or refractory mantle cell lymphoma patients: A retrospective study of the Spanish experience. Ann Hematol 2014;93(9):1551-8. Abstract
Goy A et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: Phase II MCL-001 (EMERGE) study. J Clin Oncol 2013;31(29):3688-95. Abstract
Goy A et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: Updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2008;20(3):520-5. Abstract
Jerkeman M et al. Ibrutinib-lenalidomide-rituximab in patients with relapsed/refractory mantle cell lymphoma: First results from the Nordic Lymphoma Group MCL6 (PHILEMON) phase II trial. Proc ASH 2016;Abstract 148.
Lee HJ et al. Phase II study of bortezomib in combination with cyclophosphamide and rituximab for relapsed or refractory mantle cell lymphoma. Oncologist 2017;22(5):549-53. Abstract
Martin P et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood 2016;127(12):1559-63. Abstract
Rule S et al. Overall survival outcomes in patients with mantle-cell lymphoma (MCL) treated with ibrutinib in a pooled analysis of 370 patients from 3 international open-label studies. Proc EHA 2016;Abstract S438.
Wang ML et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013;369(6):507-16. Abstract
Wang M. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: A phase 1/2 clinical trial. Lancet Oncol 2012;13:716-23. Abstract
Brad S Kahl, MD
Barf T et al. Acalabrutinib (ACP-196): A covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile. J Pharmacol Exp Ther 2017;363(2):240-52. Abstract
Cheson BD et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J Clin Oncol 2014;32(27):3059-68. Abstract
Wang M et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): A single-arm, multicenter, phase 2 trial. Lancet 2018;391(10121):659-67. Abstract
Wang M et al. Efficacy and safety of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma in the phase 2 ACE-LY-004 study. Blood 2017;130(Suppl 1):155. Abstract
Jeremy Abramson, MD
Abramson JS et al. Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL. Proc ASCO 2018;Abstract 7505.
Bentz M et al. t(11;14)-positive mantle cell lymphomas exhibit complex karyotypes and share similarities with B-cell chronic lymphocytic leukemia. Genes Chromosomes Cancer 2000;27(3):285-94. Abstract
Cunningham D et al. Results of the mantle cell lymphoma subset from a phase 2a study of copanlisib, a novel PI3K inhibitor, in patients with indolent and aggressive lymphoma. Blood 2015;126(23):3935. Abstract
Davids MS et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol 2017;35(8):826-33. Abstract
Dreyling M et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol 2017;28(9):2169-78. Abstract
Eyre T et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma post BTK inhibition therapy. Proc EHA 2018;Abstract S855.
Gopal AK et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014;370(11):1008-18. Abstract
Leonard JP et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood 2012;119(20):4597-607. Abstract
Li Y et al. FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma. Oncogene 2016;35(48):6223-34. Abstract
Morschhauser F et al. Clinical activity of abemaciclib (LY2835219), a cell cycle inhibitor selective for CDK4 and CDK6, in patients with relapsed or refractory mantle cell lymphoma. Blood 2014;124(21):3067. Abstract
Portell CA et al. Initial report of a multi-institutional phase I/Ib study of ibrutinib with venetoclax in relapsed or refractory mangle cell lymphoma. Blood 2016;128(22):2958. Abstract
Tam CS et al. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med 2018;378(13):1211-23. Abstract
Turtle CJ et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med 2016;8(355):355ra116. Abstract